- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Posterior Synechiae
Posterior synechiae describes the abnormal adhesion of the iris to the anterior capsule of the lens, ciliary body, or other intraocular parts. Protheragen offers comprehensive services for the development of diagnostics and therapeutics targeting posterior synechiae.
Posterior synechiae is the pathological adhesion of the iris to the anterior lens capsule. This condition frequently occurs as an outcome of anterior uveitis, especially in instances of moderate-severe bacterial keratitis. The formation of these adhesions can result in serious complications of the eye such as pupillary block glaucoma. The development of synechiae suggests chronic or recurrent inflammation, however, in some instances they may form within days due to intense inflammation.
Fig.1 Technique called retroiridian staining and synechiolysis for posterior synechiae research. (Alza A. G., 2024)
Posterior synechiae pathogenesis is associated with inflammatory processes that take place in the eye. Inflammation within the anterior chamber brings about the liberation of different mediators that induce fibrinogen, clot and fibroblast proliferation. These factors help in the development of adhesion between the iris and lens capsule. There is great chance of synechiae development when the aqueous humor protein content is elevated. If the adhesions encircle the entire pupil, iris bombé can occur which blocks aqueous fluid flow into the anterior chamber, thus leading to secondary glaucoma.
| Therapeutics | Target | Description | Stage |
| Prednisolone Acetate | Inflammation | A potent corticosteroid used topically to reduce inflammation and dissolve fibrin, helping to prevent and break posterior synechiae. | Approved |
| Atropine | Iris Sphincter Muscle | A cycloplegic agent that paralyzes the iris sphincter muscle, allowing the pupil to dilate and preventing adhesions. | Approved |
| Phenylephrine | Iris Radial Muscle | A sympathomimetic drug used in combination with cycloplegics to break posterior synechiae by enhancing mydriasis. | Approved |
| Dexamethasone (Ozurdex) | Inflammation | A sustained-release intravitreal implant used for posterior uveitis and other inflammatory conditions, providing long-term anti-inflammatory effects. | Approved |
| Triamcinolone Acetonide | Inflammation | An intravitreal injection used to reduce inflammation in posterior uveitis and other retinal conditions. | Approved |
| Beta-Blockers | Intraocular Pressure | Used to manage elevated intraocular pressure, especially after glaucoma surgery, as they do not exacerbate inflammation. | Approved |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Here at Protheragen, we know that no two clients have the same research needs. These specific needs are addressable within the scope of our custom services which offer flexible and creative solutions tailored to each client. From the creation of a new diagnostic tool to the refinement of a therapeutic drug, our team collaborates with the clients to formulate and execute strategies to fulfill the clients' objectives.
Protheragen's preclinical research services for posterior synechiae are designed to provide robust and reliable data to support the development of effective therapeutics. Our team of experts utilizes state-of-the-art techniques to model and study the pathogenesis of posterior synechiae. We offer a range of preclinical studies, including efficacy and safety evaluations of potential therapeutic agents. If you are interested in our services, please feel free to contact us.
Reference
Copyright © Protheragen. All rights reserved.
